Wang 2018c.

Methods	Study design: Randomised clinical trial Study duration: January 2016 to January 2017 Duration of follow‐up: 1 year Setting: Hospital
Participants	Inclusion criteria: Tumour number ≤ 3; tumour diameter of 5‐9 cm Exclusion criteria: With mental diseases; abnormal cardiac function Age (mean ± SD, range): TACE + RFA: 47.6 ± 6.8 years, 23‐66 years; TACE alone: 48.7 ± 6.5 years, 22‐68 years Male (n/total): TACE + RFA: 40/50; TACE alone: 36/50 Child‐Pugh Class (patients): Class A: TACE + RFA: 11; TACE: 10 Class B: TACE + RFA: 4; TACE: 5
Interventions	TACE + RFA group (n = 50): TACE: Chemotherapeutic drugs: oxaliplatin, mitomycin, and adriamycin RFA: Ultrasound‐guided RFA TACE group (n = 50): Chemotherapeutic drugs: oxaliplatin, mitomycin, and adriamycin
Outcomes	Tumour response, classified as complete response, partial response, stable disease, and progression Quality of life 1‐year survival rate Adverse events
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.